Fig. 1From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitusStudy design; T2DM type 2 diabetes, CV cardiovascular, AHA antihyperglycemic agent, MF metformin, PIO pioglitazone, AGI alpha-glucosidase inhibitor, SGLT2i sodium–glucose co-transporter 2 inhibitor, SU sulfonylurea, q.w. once weekly, R randomizationBack to article page